Skip to main content
Smart Investors Daily
MR

NASDAQ · MRVI

Maravai LifeSciences Holdings, Inc.

Healthcare · Biotechnology

$7.40

Down-$0.14 (-1.86%)

Updated Nov 17, 2026, 5:34 AM

SID Score

5.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.03B
P/E ratio
-4.43
Dividend yield
0.00%
52-week range
$2.80 – $9.42
Volume
1.51M
Avg. volume
1.5M

Price performance · MRVI

MRVI price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

MRVI closed at $7.40 after 21 trading sessions, up 5.87% for the selected period.

Last close
$7.40
Period change
+5.87%
Period low
$6.98
Period high
$8.50
Daily close
View OHLC price history
MRVI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$7.295$7.5999$7.09$7.401.51M
Nov 13, 2026$7.73$7.75$7.385$7.541.99M
Nov 12, 2026$7.93$7.93$7.60$7.682.5M
Nov 11, 2026$7.96$8.18$7.68$7.702.04M
Nov 10, 2026$7.87$8.01$7.62$7.861.75M
Nov 9, 2026$7.50$8.16$7.49$8.022.15M
Nov 6, 2026$7.02$7.62$7.01$7.521.94M
Nov 5, 2026$6.85$7.57$6.80$6.983.21M
Nov 4, 2026$7.73$7.89$7.275$7.723.62M
Nov 3, 2026$7.33$7.755$7.33$7.451.91M
Nov 2, 2026$7.81$7.99$7.155$7.192.29M
Oct 30, 2026$8.34$8.48$7.68$7.811.7M
Oct 29, 2026$8.49$8.62$8.285$8.461.39M
Oct 28, 2026$8.23$8.525$8.15$8.502.78M
Oct 27, 2026$7.60$8.28$7.475$8.263.11M
Oct 26, 2026$7.32$7.60$7.32$7.581.29M
Oct 23, 2026$7.03$7.33$6.98$7.321.45M
Oct 22, 2026$7.44$7.61$6.73$7.073.92M
Oct 21, 2026$7.18$7.615$7.18$7.571.7M
Oct 20, 2026$6.99$7.595$6.985$7.202.02M
Oct 19, 2026$6.79$7.02$6.69$6.991.35M

Latest MRVI news

The latest Smart Investors Daily articles mentioning MRVI.

MRVI research

Overview

Company profile and research snapshot.

Company profile

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$15.50
Implied upside
—
Analysts
—
MRVI recent ratings
DateFirmRatingTarget
Nov 12, 2026KeybancOverweight—
Sep 9, 2026UBSNeutral—
Aug 7, 2026Wells FargoOverweight—
May 8, 2026Wells FargoOverweight—
Dec 15, 2025Wells FargoOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 6, 2026

Why Maravai LifeSciences Holdings (MRVI) Is Up After Raising Revenue Guidance

Maravai LifeSciences Holdings raised its 2026 revenue outlook on 4 November 2026 to a range of US$212.0 million to US$216.0 million and reported third-quarter sales of US$45.85 million and a reduced net loss of US$13.84 million. The nine-month figures showed sales of US$163.13 million and a smaller cumulative net loss of US$29.99 million, which gives investors more detail on how Maravai LifeSciences Holdings is managing costs while supporting demand across its nucleic acid and biologics...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.